Keywords: MRSA market, Forest, AstraZeneca, Takeda, Truis, Pfizer, Ceftaroline, Torezolid, Zyvox
Uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive MRSA drug market to $752 million in 2019
Article | 01 July 2010
The uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the sales of methicillin-resistant Staphylococcus aureus ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
